Lake Bluff, IL, United States of America

Jieyi Wang

This inventor holds 23 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Lyvgen Biopharma Holdings Limited. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jieyi Wang. Retrieved from https://idiyas.com/inventor/jieyi-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 69.6

 

 

Average Co-Inventor Count = 3.6

ph-index = 7

Forward Citations = 283(Granted Patents)


Location History:

  • Gurnee, IL (US) (2001 - 2009)
  • Lake bluff, IL (US) (2005 - 2015)
  • Belmont, CA (US) (2017 - 2024)

Company Filing History:


Years Active: 2001-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-CD40 Antibodies
Cancer Immunotherapy
Tumor Microenvironment
Immune Response Enhancers
Protein Kinase Inhibitors
Anti-4-1BB Antibodies
Anti-PD-1 Antibodies
Antiangiogenic Peptides
Bi-Specific Antibodies
Kinase Activity Inhibitors
Prolactin Receptor Binding
Dual Variable Domain Immunoglobulins
23 patents (USPTO):Explore Patents

Title: Innovations in Immunotherapy: The Contributions of Jieyi Wang

Introduction

Jieyi Wang, based in Lake Bluff, IL, is a prolific inventor in the field of immunotherapy, with a remarkable portfolio comprising 22 patents. His groundbreaking work focuses on therapeutic agents and methods aimed at enhancing immune responses within the tumor microenvironment, contributing significantly to advancements in treating cancer and immune disorders.

Latest Patents

Among his latest patents, one is titled "Therapeutic agents and methods for enhancing immune responses in tumor microenvironment - Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB." This patent details methods for selectively activating immune responses by targeting specific immune cell surface receptors. Another noteworthy patent is "Anti-CD40 antibodies and uses thereof," where he discloses agnostic anti-CD40 antibodies designed to enhance CD40 signaling and, consequently, immune responses. These inventions are pivotal in the treatment strategies for diseases, notably cancer and various immune disorders.

Career Highlights

Jieyi Wang has made substantial contributions during his tenure at notable companies like Abbott Laboratories Corporation and AbbVie Inc. His innovative work has not only advanced the field of immunotherapy but has also established him as a leading figure in developing new treatment paradigms.

Collaborations

Throughout his career, Jieyi has collaborated with esteemed professionals, including George S. Sheppard and Megumi Kawai. These collaborations have fostered an environment of creativity and innovation, enabling the development of novel therapeutic interventions.

Conclusion

Jieyi Wang’s contributions to the field of immunotherapy through his patents reflect a commitment to enhancing treatment methodologies for complex diseases. His work continues to inspire the next generation of researchers and inventors striving to make a significant impact in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…